Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TriSalus Life Sciences ( (TLSI) ) has provided an announcement.
On June 12, 2025, TriSalus Life Sciences, Inc. held its Annual Meeting of Shareholders, where 73.2% of the total outstanding shares were represented. During the meeting, two directors were elected for three-year terms, and the appointment of Grant Thornton, LLP as the independent registered accounting firm for 2025 was ratified.
The most recent analyst rating on (TLSI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.
Spark’s Take on TLSI Stock
According to Spark, TipRanks’ AI Analyst, TLSI is a Neutral.
TriSalus Life Sciences’ overall score reflects significant financial challenges, despite strong revenue growth and positive strategic developments. The lack of profitability and negative equity are major risks, while technical indicators and valuation suggest a neutral to cautious outlook.
To see Spark’s full report on TLSI stock, click here.
More about TriSalus Life Sciences
TriSalus Life Sciences, Inc. operates in the life sciences industry, focusing on developing innovative therapies and solutions for patients with challenging conditions.
Average Trading Volume: 49,750
Technical Sentiment Signal: Sell
Current Market Cap: $196.4M
Find detailed analytics on TLSI stock on TipRanks’ Stock Analysis page.